CN stock · Healthcare sector · Biotechnology
Company Logo

BeiGene, Ltd.

BGNENASDAQ

133.96

USD
+2.70
(+2.06%)
Market Closed
-7.17P/E
-11Forward P/E
-0.28P/E to S&P500
13.822BMarket CAP
- -Div Yield
Upcoming Earnings
8 Aug-14 Aug
Shares Short
5/13/22
2.04M
Short % of Float
- -
Short % of Shares Outs.
1.98%
% Held by Insiders
18.47%
% Held by Institutions
54.64%
Beta
0.85
PEG Ratio
-0.25
52w. high/low
426.56/118.18
Avg. Daily Volume
0.35M
Return %
Stock
S&P 500
1 year
(62.04)
(3.64)
3 years
6.61
43.84
5 years
258.85
68.07
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
37.89
22.51
118.95
29.58
220.10
95.34
210.35
108.00
322.98
118.55
426.56
222.21
275.71
118.18
Currency: USD
- -
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
0.12
0.78
0.28
0.03
5.23
3.58
7.13
3.70
14.09
9.18
Earnings per share
- -
- -
- -
- -
- -
- -
- -
(0.08)
(1.10)
(1.81)
(3.00)
(2.04)
(12.15)
(15.80)
(19.13)
(16.93)
(20.02)
FCF per share
- -
- -
- -
- -
- -
- -
- -
0.04
(0.56)
(1.43)
(2.85)
(1.01)
(12.42)
(15.13)
(18.12)
(15.56)
(18.11)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
0.00
0.04
0.17
0.59
1.29
2.54
2.64
2.74
- -
2.36
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
(0.42)
1.55
2.36
8.89
14.71
31.37
16.02
46.35
74.79
49.97
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
92
17
32
40
46
55
60
83
83
96
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(9.9)
(29.5)
(12.9)
(8.9)
(10.8)
(19.5)
(7.2)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.4)
(1.3)
(0.5)
(0.4)
(0.3)
(0.7)
(0.3)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
11
13
9
1
238
198
428
309
1,176
877
Operating margin
- -
- -
- -
- -
- -
- -
- -
(49.0)%
(120.9)%
(643.7)%
(10,940.2)%
(41.3)%
(356.1)%
(224.2)%
(536.7)%
(122.3)%
(238.1)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
2
2
2
2
5
10
19
32
1
40
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
(7)
(18)
(57)
(119)
(93)
(674)
(949)
(1,597)
(1,413)
(1,914)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.0)%
(2.5)%
2.3%
(0.7)%
1.1%
1.8%
0.4%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
(67.2)%
(140.2)%
(647.7)%
(11,141.8)%
(39.1)%
(339.9)%
(221.5)%
(517.0)%
(120.2)%
(234.0)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
(27)
34
71
339
764
1,697
862
3,885
- -
5,572
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
15
14
6
17
155
190
241
184
- -
242
Equity (m)
- -
- -
- -
- -
- -
- -
- -
(39)
26
74
353
670
1,739
962
3,869
6,243
5,886
ROIC
- -
- -
- -
- -
- -
- -
- -
21.8%
(36.6)%
(68.5)%
(32.2)%
(10.6)%
(33.9)%
(73.8)%
(35.3)%
(16.3)%
(28.7)%
Return on capital
- -
- -
- -
- -
- -
- -
- -
(36.8)%
(27.5)%
(47.9)%
(29.4)%
(8.8)%
(30.8)%
(59.0)%
(28.8)%
(16.6)%
(23.8)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
19.4%
(70.9)%
(76.8)%
(33.8)%
(13.9)%
(38.7)%
(98.6)%
(41.3)%
(22.6)%
(32.5)%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
9 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 2,136
Total assets
$ 8,021
Long-term debt
$ 242
Cash and equiv.
$ 4,347
Goodwill
$ 0
Retained earnings
$ (5,400)
Common stock
102
Enterprise Value
$ 9,716
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
983
4,651
0
Receivables
73
80
- -
Inventory
29
89
- -
Other
89
905
(618)
Current assets
1,173
4,961
- -
Acc. Payable
122
232
262
Debt due
11
349
- -
Other
177
494
(262)
Current liabilities
310
1,075
- -
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
280.83%
88.03%
- -
Cash flow
(14.13)%
370.48%
- -
Earnings
(11.49)%
180.33%
- -
Dividends
- -
- -
- -
Book value
61.35%
119.61%
- -
Insider Trading
Type
Shares
Date
Wang Lai
Exempt
999,999
05/17/22
Wang Lai
Exempt
999,999
05/17/22
Wang Lai
Exempt
233,948
05/17/22
Wu Xiaobin
Sale
500
05/05/22
Wu Xiaobin
Sale
100
05/05/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
52
66
91
100
309
2021
606
150
206
214
1,176
2022
307
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(4.36)
(4.02)
(5.09)
(5.66)
(19.13)
2021
0.80
(5.75)
(4.96)
(7.02)
(16.93)
2022
(4.24)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. John V. Oyler
Full-time employees:
8,300
City:
Beijing
Address:
No.30 Science Park Road
IPO:
Feb 3, 2016
Website:
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Recent News